General hospital psychiatry
July 24, 2025
Shizhen Wang, Mengru Wu, Jixiang Wei et al.
6 citations
Electronic mindfulness-based cognitive therapy (eMBCT) reduces anxiety and depression in adults with small but significant effects that are sustained over time. A meta-analysis of 12 randomized controlled trials with 2,588 participants found that eMBCT lowered anxiety (standardized mean difference -0.33) and depression (-0.34) compared to usual care, waitlist, or active interventions. Greater baseline symptom severity was linked to larger improvements. Short- and long-term benefits were observed, but medium-term effects were not significant. The findings suggest eMBCT is an effective scalable treatment, though further research is needed to enhance medium- and long-term outcomes and tailor interventions for flexible patient care.
General hospital psychiatry
January 1, 2025
Shizhen Wang, Wangjie Xia, Jian Zhang et al.
6 citations
A meta-analysis of 10 randomized controlled trials with 1314 cancer patients found that internet-based mindfulness interventions reduce anxiety and depression. The interventions were most effective when sessions lasted under 45 minutes and the program duration was within 8 weeks. Therapist-guided interventions, especially those with synchronous online interaction, produced greater improvements than unguided ones. The analysis reports moderate effect sizes for both anxiety and depression. The authors note that medium- to long-term efficacy requires further validation through high-quality research.
Frontiers in pharmacology
January 1, 2026
Yang Qu, Shujin Li, Li Tian et al.
A meta-analysis of nine randomized controlled trials involving 1,449 patients found that esketamine improves symptoms in treatment-resistant depression but significantly increases dose-dependent adverse events. Compared with controls, esketamine raised the risk of nine adverse events including nausea, dissociation, dizziness, vertigo, elevated blood pressure, and somnolence. Risks were strongly dose-dependent: the high-dose group (≥56 mg or 0.40 mg/kg) had a greater risk than the low-dose group (≤28 mg or 0.20 mg/kg), with relative risk for nausea of 3.72 versus 1.69 and for dissociation of 10.65 versus 3.27. Although esketamine improved clinical response rate (relative risk = 1.94), it increased treatment discontinuation due to adverse events by 2.22-fold. Clinical use should adopt personalized dosing strategies balancing efficacy and tolerability.